Zoledronic Acid belongs to the bisphosphonate class and primarily targets bones. It inhibits osteoclast-mediated bone resorption due to its high affinity for mineralized bone. After intravenous administration, it rapidly localizes at areas of high bone turnover. Zoledronic Acid’s main target is the enzyme farnesyl pyrophosphate synthase in osteoclasts. Its long-lasting effect is due to its strong binding to bone minerals.
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Aclasta is used for the following conditions:
The optimal treatment duration is not fully established. For patients with a low fracture risk, discontinuing the drug after 3–5 years of use should be considered.
Use only as directed by a registered physician.
Consider re-treatment in cases of relapse or inadequate response, based on serum alkaline phosphatase levels or persistent symptoms.
Aclasta is used to treat:
Zoledronic acid is a potent amino bisphosphonate that inhibits bone resorption by reducing osteoclast activity and preventing skeletal calcium release caused by tumors.
If you miss a scheduled dose, consult your doctor for guidance.
Common:
Rare but Serious:
Symptoms of overdose include renal impairment, hypocalcemia, hypophosphatemia, and hypomagnesemia. Treat with:
- Dose: 5 mg as a single infusion over 15 minutes.
- Calcium and Vitamin D: Administer 1,500 mg elemental calcium and 800 IU vitamin D daily, especially within 2 weeks after administration.
- Re-treatment: For relapsed patients, an additional 5 mg infusion may be given after at least 1 year from the initial dose.
- Dose: 5 mg as a single infusion over at least 15 minutes, administered once yearly.
- Calcium and Vitamin D: Ensure adequate intake of these supplements.
- Timing: Begin therapy 2 or more weeks after hip fracture repair.
- Loading Dose: Administer 50,000–125,000 IU of vitamin D orally or intramuscularly before the first infusion.
- Dose: 5 mg as a single infusion once every 2 years.
- Safety and efficacy not established.
- Creatinine Clearance (CrCl) > 35 mL/min: No dose adjustment is needed.
- CrCl < 35 mL/min: Contraindicated.
- Safety and efficacy not established.
⚠️Disclaimer:
At ePharma, we’re committed to providing accurate and accessible health information. However, all content is intended for informational purposes only and should not replace medical advice from a qualified physician. Please consult your healthcare provider for personalized guidance. We aim to support, not substitute, the doctor-patient relationship.